LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

Home・Akcijų sąrašas・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

9.6 0.95

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.48

Max

9.77

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.1B -722M
Pardavimai	-250M 156M
P/E Sektoriaus vid.	7.603 51.415
Pelnas, tenkantis vienai akcijai	0.141
Pelno marža	-461.478
Darbuotojai	435
EBITDA	-968M -702M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+154.89% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-157M 2.2B
Ankstesnė atidarymo kaina	8.65
Ankstesnė uždarymo kaina	9.6

Naujienos nuotaikos

By Acuity

20%

80%

45 / 346 reitingas Healthcare

BioCryst Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-13 22:54; UTC

Uždarbis

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

2026-05-13 23:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-13 23:51; UTC

Rinkos pokalbiai

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-13 23:17; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-13 23:16; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

2026-05-13 23:15; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

2026-05-13 23:14; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

2026-05-13 23:02; UTC

Rinkos pokalbiai

Uždarbis

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

2026-05-13 22:59; UTC

Rinkos pokalbiai

Uždarbis

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

2026-05-13 22:24; UTC

Uždarbis

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Organic Revenue Growth 25%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Revenue Growth 47%>XRO.AU

2026-05-13 22:22; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

2026-05-13 22:18; UTC

Uždarbis

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

2026-05-13 22:16; UTC

Uždarbis

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

2026-05-13 22:13; UTC

Uždarbis

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

2026-05-13 22:12; UTC

Uždarbis

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero Did Not Declare a Dividend>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

2026-05-13 22:09; UTC

Uždarbis

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

2026-05-13 22:00; UTC

Uždarbis

Cisco to Shed Jobs for All-In AI Push -- Update

2026-05-13 21:11; UTC

Uždarbis

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

BioCryst Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

154.89% į viršų

12 mėnesių prognozė

Vidutinis 22.43 USD 154.89%

Aukščiausias 32 USD

Žemiausias 13 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioCryst Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių BioCryst Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

45 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.